Beta-alanine supplementation is well established for elevating muscle carnosine concentrations and enhancing high-intensity exercise capacity. However, acute high-dose ingestion often results in paresthesia, a transient tingling sensation that, while harmless, can deter adherence and limit consumer acceptance.
TriBsyn® beta-alanine, formulated with Hydro Oleo technology, has been clinically evaluated to determine whether its improved bioavailability can achieve target plasma concentrations while mitigating paresthesia. This Science Spotlight reviews the tolerability findings from a randomized, controlled clinical trial and their implications for product development (TriBsyn, 2025a).
Methods: Study Design and Tolerability Assessment
The tolerability data were collected in a randomized, double-blind, single-dose, three-treatment, three-way crossover pharmacokinetic study in healthy older adults. Each participant ingested one of three interventions under fasting conditions:
- 400 mg TriBsyn® (Hydro Oleo encapsulated beta-alanine)
- 400 mg conventional beta-alanine
- 1200 mg high-dose conventional beta-alanine
Paresthesia severity was assessed using the Visual Analogue Scale (VAS), where 0 = no sensation and 10 = extreme tingling, and the Quality of Life Symptom Index (QLSI) to capture broader symptom impact. These measurements were taken at intervals consistent with PK sampling to directly correlate plasma concentrations with sensory experience (TriBsyn, 2025b).
Results: Reduced Sensory Side Effects With Higher Bioavailability
VAS Scores
- TriBsyn® (400 mg): VAS ≈ 0.62
- Conventional 400 mg: VAS ≈ 2.02
- High-Dose Conventional 1200 mg: VAS ≈ 4.01
These findings indicate that TriBsyn® achieved approximately 4.5-fold greater plasma exposure compared to the standard 400 mg dose of beta-alanine. Moreover, it exceeded the exposure levels of the 1200 mg dose while eliciting lower paresthesia scores. (TriBsyn, 2025a).
QLSI Findings
QLSI scores showed no significant adverse impact on quality of life with TriBsyn®, reinforcing that its delivery method mitigates sensory discomfort while preserving efficacy.
Mechanistic Considerations
The reduction in paresthesia is likely related to TriBsyn®’s sustained release profile and dual absorption pathways afforded by Hydro Oleo™ technology. By modulating the rate at which beta-alanine enters systemic circulation, TriBsyn® helps avoid the rapid plasma spikes associated with cutaneous sensory nerve activation, the proposed mechanism behind beta-alanine–induced tingling (TriBsyn, 2025b).
Formulation Implications
For product developers, these findings have several practical applications:
- Broader demographic targeting: Beta-alanine’s paresthesia-free performance makes it viable for older adults, clinical nutrition applications, as well as healthy aging and active nutrition users sensitive to sensory effects.
- Multi-ingredient stack compatibility: Lower dosing with sustained exposure frees formulation space for other active compounds without exacerbating tingling.
- Improved compliance: Products can deliver effective beta-alanine exposure without discouraging repeat use due to discomfort.
Conclusion
Clinical evidence supports that TriBsyn® beta-alanine delivers superior plasma beta-alanine concentrations at a 400 mg dose with minimal incidence of paresthesia. This combination of high efficacy and improved tolerability provides significant value in sports performance, healthy aging, and multi-ingredient formulations where consumer comfort is essential.
References
TriBsyn. (2025a). Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn® Delivering Exceptional Bioavailability, Increased Efficiency, and Paresthesia Elimination. Retrieved from https://www.tribsyn.com/2025/03/05/natural-alternatives-international-and-carnosyn-brands-publish-clinical-research-demonstrating-tribsyn-delivering-exceptional-bioavailability-increased-efficiency-and-paresthesia/
TriBsyn. (2025b). The TriBsyn® Innovation White Paper. Retrieved from https://www.tribsyn.com/wp-content/uploads/2025/04/The-TriBsyn%E2%84%A2-Innovation-White-Paper.pdf